Search results
Results from the WOW.Com Content Network
Edwards Lifesciences Corporation (NYSE:EW) shares are trading higher on Thursday. Stifel analyst Rick Wise upgraded Edwards from Hold to Buy, raising the price forecast to $90 from $75. Wise ...
On Wednesday, during its annual investor conference, Edwards Lifesciences Corporation (NYSE:EW) detailed its strategy for sustained long-term growth and innovations in structural heart therapies.
Edwards Lifesciences (EW) continues to register strong momentum in TMTT on a portfolio of differentiated therapies, positive pivotal trial results and favorable real-world clinical outcomes.
Easing staffing issues at U.S. hospitals have boosted non-urgent procedures delayed by the pandemic, but heart surgeries have not recovered as fast as some others, hurting medical device makers ...
BRUSSELS (Reuters) -Edwards Lifesciences is working with EU antitrust regulators after they raided one of its facilities in an EU country a week ago, the U.S. medical device maker said on Tuesday.
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring. It developed the SAPIEN transcatheter aortic heart valve made of cow tissue within a balloon-expandable, cobalt-chromium frame, deployed via catheter . [ 4 ]
Investors continue to be optimistic about Edwards Lifesciences' (EW) performance. For premium support please call: 800-290-4726 more ways to reach us
For premium support please call: 800-290-4726 more ways to reach us